Metabolic Dysfunction and CKD: Understanding the Critical Connection Between Liver and Kidney Health

What Links Metabolic Dysfunction and CKD?

The relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) has emerged as a significant area of clinical research, particularly as obesity rates continue to rise globally. A recent longitudinal cohort study from Japan has provided compelling evidence that MASLD serves as an independent risk factor for CKD development, offering important insights for clinical practice. This comprehensive investigation, part of the NAFLD in the Gifu Area, Longitudinal Analysis (NAGALA) study, tracked 15,873 participants over a five-year period to evaluate how different classifications of steatotic liver disease impact kidney function outcomes. The findings reveal critical connections between metabolic dysfunction, liver health, and kidney disease that could inform future preventative strategies and patient management approaches in both hepatology and nephrology.

Which Methods Underpinned the NAGALA Study?

The study's methodology involved categorizing participants into eight distinct groups based on the presence of hepatic steatosis (S), cardiometabolic risk factors (C), and alcohol consumption patterns (A). This classification system aligns with the recent Delphi consensus that proposed renaming steatotic liver diseases to better reflect their underlying pathophysiology. Participants underwent comprehensive evaluations including blood tests, abdominal ultrasonography, and detailed questionnaires about lifestyle factors. The primary outcome was the development of CKD, defined as an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m² or persistent proteinuria for at least three months. The study population was predominantly male (58.7%), with a mean age of 43.66 years and a mean body mass index (BMI) of 22.44 kg/m². Notably, 38.4% of participants had a BMI exceeding 23 kg/m², which is considered a risk threshold in Asian populations. The researchers employed logistic regression models adjusted for age, sex, baseline eGFR, smoking status, and exercise habits to assess the relationship between the different steatotic liver disease categories and CKD incidence.

What Do the Results Tell Us?

The results revealed a striking pattern of CKD development across the different groups. Group 8, which comprised participants with MASLD (hepatic steatosis, minimal alcohol intake, and at least one cardiometabolic risk factor), demonstrated the highest CKD incidence at 9.5%. This was followed by Group 7 (MetALD—MASLD with light alcohol consumption) at 8.3%, and Groups 2 and 3 (both at 7.8%). After adjusting for covariates, Group 8 participants showed a significantly elevated risk of CKD with an odds ratio of 1.37 (95% CI 1.12–1.67, p=0.002) compared to Group 1 (the reference group with no steatosis and no cardiometabolic risk). Interestingly, while Group 7 showed a trend toward increased CKD risk (OR 1.10, 95% CI 0.70–1.74), this association did not reach statistical significance (p=0.67). Similarly, Group 2 (no steatosis but with cardiometabolic risk) showed a tendency toward CKD development (OR 1.16, 95% CI 0.98–1.37, p=0.07), suggesting that cardiometabolic factors play a crucial role in kidney function decline regardless of liver fat accumulation. Age and baseline eGFR emerged as significant independent predictors of CKD development, with odds ratios of 1.04 (p<0.001) and 0.88 (p<0.001), respectively.

How Do These Findings Influence Clinical Practice?

The implications of these findings are substantial for clinical practice, particularly in the management of patients with metabolic disorders. The study suggests that the presence of cardiometabolic risk factors, rather than alcohol consumption, may be the primary driver of CKD development in patients with steatotic liver disease. This aligns with previous research indicating that metabolic syndrome components contribute significantly to both liver and kidney pathology through shared pathophysiological mechanisms involving insulin resistance, systemic inflammation, oxidative stress, and dyslipidemia. The relationship between alcohol consumption and kidney function remains complex, with the current study unable to draw definitive conclusions about high alcohol intake groups due to limited sample sizes. Previous research has shown conflicting results, with some studies suggesting that moderate alcohol consumption might have protective effects against CKD progression, while excessive intake clearly increases risk. These nuanced relationships highlight the need for personalized risk assessment in patients with varying degrees of alcohol consumption and metabolic dysfunction.

The study's findings regarding non-obese NAFLD (now MASLD) are particularly relevant for Asian populations, where this phenotype is more prevalent compared to Western countries. In Japan and other Asian regions, individuals with lean MASLD often exhibit increased visceral adiposity, reduced muscle mass, and impaired glucose tolerance despite having a normal BMI. These characteristics may complicate kidney function assessment, as eGFR calculations based on creatinine can overestimate kidney function in patients with lower muscle mass. The researchers suggest that measuring cystatin C, which is less influenced by muscle mass, might provide a more accurate assessment of kidney function in this population. Furthermore, the observation that lean NAFLD patients have the highest all-cause mortality in Japanese cohorts underscores the importance of identifying and managing these seemingly "lower-risk" individuals who may actually face significant health challenges. Personalized approaches incorporating medical nutritional therapy and targeted exercise regimens could be crucial for mitigating CKD risk in patients with MASLD, particularly in those with non-traditional risk profiles.

What Limitations Affect the Study's Applicability?

Several limitations of the study warrant consideration when interpreting its findings. The participant population was limited to individuals undergoing health checkups in the Gifu region of Japan, potentially introducing selection bias and limiting generalizability to other populations. The study also lacked comprehensive dietary data beyond alcohol intake, which is significant given that dietary patterns can substantially influence both liver health and kidney function. For instance, consumption of low-fat, low-sugar dairy products has been associated with protection against MASLD, while plant-based protein diets may benefit those at risk for CKD. Additionally, while fasting plasma glucose was measured, postprandial glucose levels were not assessed, potentially missing important information about glucose metabolism, as impaired glucose tolerance has been shown to be a stronger predictor of cardiovascular disease than impaired fasting glucose. Future research addressing these gaps could provide more nuanced insights into the complex relationships between metabolic dysfunction, liver health, and kidney disease progression.

Can These Insights Shape Future Prevention Strategies?

The identification of MASLD as an independent risk factor for CKD development raises important questions about screening and preventive strategies. Could routine liver ultrasound or non-invasive fibrosis assessments become standard components of CKD risk stratification in patients with metabolic risk factors? How might the integration of liver health markers into kidney disease risk calculators improve their predictive accuracy? Additionally, the study's findings suggest potential therapeutic targets for intervention. Addressing the underlying metabolic dysfunction through lifestyle modifications, pharmacological approaches targeting insulin resistance, or emerging therapies for MASLD might simultaneously reduce the risk of both liver and kidney complications. The interplay between cardiometabolic risk factors, hepatic steatosis, and kidney function highlights the need for multidisciplinary approaches to patient care, involving hepatologists, nephrologists, endocrinologists, and primary care physicians working collaboratively to address these interconnected health challenges. As our understanding of these relationships continues to evolve, early identification and comprehensive management of patients with MASLD will be essential for reducing the global burden of CKD.

Summary

The NAGALA study, a comprehensive Japanese research project, investigated the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) in 15,873 participants over five years. The study found that patients with MASLD showed the highest CKD incidence at 9.5%, with an odds ratio of 1.37 compared to those without steatosis or cardiometabolic risk factors. The research revealed that cardiometabolic risk factors, rather than alcohol consumption, appear to be the primary driver of CKD development in patients with steatotic liver disease. The findings particularly impact Asian populations, where non-obese NAFLD is more prevalent, and suggest the need for personalized risk assessment and management strategies. The study's implications emphasize the importance of early identification and comprehensive management of patients with MASLD to reduce CKD risk.